News
-
-
PRESS RELEASE
Kering : Communiqué de presse - Résultats annuels 2024
-
PRESS RELEASE
Vente-unique.com boucle un 1er trimestre 2024-2025 record avec toujours une forte dynamique commerciale
Le Groupe Vente-unique.com annonce un volume d'affaires global en hausse de 14,5% et un chiffre d'affaires consolidé en progression de 11,3% pour le 1er trimestre 2024-2025, confirmant sa confiance pour l'avenir -
-
PRESS RELEASE
EQS-Adhoc: ams-OSRAM AG: ams OSRAM delivers cost savings ahead of plan, positive FCF in FY24, Q4 revenues & profitability above mid-point of guided range and expects FCF exceeding EUR 100m in 2025
ams OSRAM AG reports cost savings ahead of plan, positive FCF in FY24, and expects FCF exceeding EUR 100m in 2025. Q4 revenues & profitability above guided range. CEO anticipates improved profitability in FY25 -
REGULATED PRESS RELEASE
bioMérieux obtient l’autorisation de la FDA américaine pour la nouvelle version de son test moléculaire ciblant les causes de la gastroentérite, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid
bioMérieux reçoit l'autorisation de la FDA américaine pour son test moléculaire BIOFIRE® FILMARRAY® Gastrointestinal Panel Mid ciblant la gastroentérite -
REGULATED PRESS RELEASE
bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid
bioMérieux receives U.S. FDA clearance for the new version of its molecular test, the BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid, targeting causes of gastroenteritis. The test detects 11 common bacteria, viruses, and parasites from one sample in about 1 hour, improving patient outcomes -
PRESS RELEASE
NORMA Group completes a challenging financial year 2024 with a stable level of profitability
NORMA Group successfully concludes 2024 with stable profitability. Preliminary figures show sales of EUR 1.2 billion, adjusted EBIT at EUR 92.3 million, and strong cash flow. Divestment of Water Management business initiated -
PRESS RELEASE
BIOVERSYS SUCCESSFULLY ADVANCES BV500 NTM PROGRAM WITH CONTINUED SUPPORT FROM CF AMR SYNDICATE
BioVersys advances BV500 NTM program with continued support from CF AMR Syndicate, developing therapies for NTM lung disease in CF patients. Company focuses on antibacterial products against MDR bacteria -
PRESS RELEASE
TUI Group: 10th consecutive quarter of Und. EBIT growth – Hotels, Cruises and TUI Musement driving improvement in FY25 Q1
TUI Group reports 10th consecutive quarter of underlying EBIT growth in FY25 Q1, driven by Hotels, Cruises, and TUI Musement. Q1 revenue up +13% to €4.9bn. Market + Airline segment shows 31% lower underlying EBIT due to investments for summer season
